Last reviewed 2026-04-20 · How we verify

Tegoprazan 50 mg

Tegoprazan 50 mg is a Potassium-Competitive Acid Blocker (P-CAB) Small molecule drug developed by First People's Hospital of Hangzhou. It is currently FDA-approved. Also known as: K-CAB, K-cab.

Tegoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits the H+/K+-ATPase enzyme, reducing gastric acid secretion.

Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by the First People's Hospital of Hangzhou. It is designed to inhibit gastric acid secretion more effectively and rapidly than traditional proton pump inhibitors (PPIs). Tegoprazan has shown promise in treating gastroesophageal reflux disease (GERD) and peptic ulcers, with clinical trials demonstrating its efficacy and safety. However, it does not have an FDA label, indicating that it may be approved or used in other regions. The drug's mechanism of action involves competitive inhibition of the H+/K+-ATPase enzyme, which is responsible for acid production in the stomach. Tegoprazan's rapid onset of action and sustained effect make it a potential alternative to existing treatments.

At a glance

Mechanism of action

Tegoprazan competes with potassium ions for binding to the H+/K+-ATPase enzyme, which is located on the luminal surface of parietal cells in the stomach. This competitive inhibition prevents the exchange of hydrogen ions for potassium ions, thereby reducing the secretion of gastric acid.

Approved indications

Pipeline indications

Common side effects

• Headache
• Diarrhea
• Nausea
• Dizziness
• Constipation

Key clinical trials

• Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
• Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study (NA)
• Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1) (PHASE4)
• Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy (PHASE4)
• Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication (PHASE2, PHASE3)
• Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori） (PHASE4)
• Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia (PHASE4)
• Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Tegoprazan 50 mg CI brief — competitive landscape report
• Tegoprazan 50 mg updates RSS · CI watch RSS
• First People's Hospital of Hangzhou portfolio CI

Frequently asked questions about Tegoprazan 50 mg

Related

• Drug class: All Potassium-Competitive Acid Blocker (P-CAB) drugs
• Target: All drugs targeting H+/K+-ATPase
• Manufacturer: First People's Hospital of Hangzhou — full pipeline
• Therapeutic area: All drugs in Gastroenterology
• Also known as: K-CAB, K-cab
• Compare: Tegoprazan 50 mg vs similar drugs
• Pricing: Tegoprazan 50 mg cost, discount & access